Skip to Content
Merck
All Photos(1)

Documents

416154

Sigma-Aldrich

Pre-mRNA Splicing Inhibitor, Isoginkgetin

The Pre-mRNA Splicing Inhibitor, Isoginkgetin, also referenced under CAS 548-19-6, blocks the spliceosome-meidated splicing process.

Synonym(s):

Pre-mRNA Splicing Inhibitor, Isoginkgetin, 8-(5-(5,7-Dihydroxy-4-oxo-4H-chromen-2-yl)-2-methoxyphenyl)-5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C32H22O10
CAS Number:
548-19-6
Molecular Weight:
566.51
MDL number:
MFCD00597035
UNSPSC Code:
12352200

Quality Level

100

Assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

yellow

solubility

DMSO: 100 mg/mL

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C32H22O10/c1-39-18-6-3-15(4-7-18)26-14-24(38)31-22(36)12-21(35)29(32(31)42-26)19-9-16(5-8-25(19)40-2)27-13-23(37)30-20(34)10-17(33)11-28(30)41-27/h3-14,33-36H,1-2H3

InChI key

HUOOMAOYXQFIDQ-UHFFFAOYSA-N

General description

A cell-permeable, naturally isolated Ginkgo biloba biflavanoid that acts as a general pre-mRNA splicing inhibitor (ICmax = 50 µM in splicing assays using HeLa nuclear extract) by blocking the spliceosome-meidated splicing process at the prespliceosome/A complex stage. Isoginkgetin treatment is shown to result in growth arrest in HEK293-derived cultures in a reversible manner without affecting cell viability (33 µM for 24 h).
A naturally isolated Ginkgo biloba biflavanoid that acts as a cell-permeable, reversible inhibitor against spliceosome-mediated pre-mRNA splicing (IC50 and ICmax = 30 and 50 µM, respectively, in splicing assays using HeLa nuclear extract) by preventing the prespliceosome A complex from recruiting the U4/U5/U6 tri-snRNP (stable nuclear RNA and its associated proteins) to form B complex. Isoginkgetin treatment is shown to result in growth arrest in HEK293-derived cultures in a reversible manner without affecting cell viability (33 µM for 24 h).

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Other Notes

Kim, H.Y., et al. 2008. Arch. Pharm. Res.31, 265.
O′Brien, K., et al. 2008. J. Biol. Chem.283, 33147.
Yoon, S,O., et al. 2006. Mol. Cancer Ther.5, 2666.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hyun Pyo Kim et al.
Archives of pharmacal research, 31(3), 265-273 (2008-04-15)
Biflavonoids belong to a subclass of the plant flavonoid family. Distribution of biflavonoids in the plant kingdom is limited to several species. Previously, some pharmacological activities of biflavonoids were described such as inhibition of histamine release from mast cells and
Kristine O'Brien et al.
The Journal of biological chemistry, 283(48), 33147-33154 (2008-10-02)
Membrane-permeable compounds that reversibly inhibit a particular step in gene expression are highly useful tools for cell biological and biochemical/structural studies. In comparison with other gene expression steps where multiple small molecule effectors are available, very few compounds have been
Sang-Oh Yoon et al.
Molecular cancer therapeutics, 5(11), 2666-2675 (2006-11-24)
Matrix metalloproteinase (MMP)-9 plays a key role in tumor invasion. Inhibitors of MMP-9 were screened from Metasequoia glyptostroboides (Dawn redwood) and one potent inhibitor, isoginkgetin, a biflavonoid, was identified. Noncytotoxic levels of isoginkgetin decreased MMP-9 production profoundly, but up-regulated the
Andrey A Parkhitko et al.
PLoS genetics, 17(2), e1009354-e1009354 (2021-02-17)
The RB1 tumor suppressor is recurrently mutated in a variety of cancers including retinoblastomas, small cell lung cancers, triple-negative breast cancers, prostate cancers, and osteosarcomas. Finding new synthetic lethal (SL) interactions with RB1 could lead to new approaches to treating

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service